Retirement Guys Formula LLC Buys 1,693 Shares of Cencora, Inc. $COR

Retirement Guys Formula LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 26.6% in the third quarter, Holdings Channel.com reports. The fund owned 8,054 shares of the company’s stock after acquiring an additional 1,693 shares during the quarter. Cencora makes up approximately 0.9% of Retirement Guys Formula LLC’s investment portfolio, making the stock its 28th biggest position. Retirement Guys Formula LLC’s holdings in Cencora were worth $2,517,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Baader Bank Aktiengesellschaft lifted its position in Cencora by 318.5% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock valued at $1,300,000 after acquiring an additional 3,300 shares in the last quarter. Voleon Capital Management LP bought a new stake in Cencora during the 1st quarter worth approximately $3,111,000. Focus Partners Wealth raised its stake in shares of Cencora by 25.8% in the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after purchasing an additional 1,171 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Cencora by 947.5% in the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after purchasing an additional 232,539 shares in the last quarter. Finally, Fiduciary Alliance LLC bought a new position in shares of Cencora in the second quarter valued at approximately $262,000. 97.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Barclays started coverage on Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price target for the company. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research note on Monday. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $373.25.

Cencora Stock Performance

NYSE COR opened at $338.07 on Friday. The company has a market capitalization of $65.58 billion, a PE ratio of 42.52, a price-to-earnings-growth ratio of 1.61 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $377.54. The company has a 50-day simple moving average of $349.47 and a 200 day simple moving average of $316.22.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the prior year, the firm earned $3.34 EPS. The company’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the completion of the transaction, the chief executive officer owned 68,059 shares in the company, valued at approximately $23,374,863.55. This represents a 6.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 20,317 shares of company stock valued at $7,009,260 over the last ninety days. 10.80% of the stock is currently owned by insiders.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.